Bristol Myers Squibb Update (BMS) – Coronavirus (COVID-19)

Dear (name),

At Bristol Myers Squibb, we are closely monitoring the evolving coronavirus (COVID-19) situation, and we are taking proactive steps to protect and support the health and well-being of people in our communities, including our employees, patients and other partners. As the medical community navigates this challenge together, our highest priority remains caring for patients. We remain fully committed to delivering our medicines and services to patients and customers in the most responsible way possible.

To this end, in an effort to help reduce the potential spread of COVID-19 across the UK and Ireland, we have moved to a remote working situation, including asking all field teams to stop in-person customer visits, until the beginning of April or as required. Many visits and interactions are being replaced by virtual/digital interactions, where possible, and some of you have already experienced this approach in the last few weeks.

Of course, we continue to operate as an organization, ensuring supply of our medicines for patients and addressing customer needs. Our systems for adverse event reporting remain in place, and our teams are maintaining business continuity to ensure your needs are met. These changes are intended to be temporary as we continue to monitor and assess the situation, and we will provide additional updates as we learn more. Additionally, for those HCPs that run Bristol-Myers Squibb Clinical Trials, you will receive an additional update in a separate communication.

It is our hope that these actions will help us continue to meet your needs for information and access to our medications, while supporting containment of COVID-19. If you have specific questions or needs, please do reach out to your local field representative, or you also can contact us at +44 (0)1895 523000.

Thank you for your partnership in our shared mission of caring for patients and our communities. We have confidence that together we all will effectively manage through this very challenging situation.

Regards,

Lynelle Hoch   Faisal Mehmud
General Manager, UK & Ireland Head of Medical Affairs, UK & Ireland
Bristol Myers Squibb   Bristol Myers Squibb

Adverse Event Reporting
UK - Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Ireland - Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie.

For Celgene Heritage Medicines: Adverse Event Reporting/Medical Information (MI) Enquiries
To report an Adverse Event in any patient or subject receiving a Celgene product please contact Celgene Drug Safety: Telephone: UK: 0808 228 9908 | Ireland: 1900 936 217 | Fax: UK: 0844 801 0468 | Ireland: 1800 936 477 | E-mail: DrugSafetyUK@celgene.com
For any medical or product related enquiries relating to a Celgene product please contact Celgene Medical Information: Telephone: UK: 0844 801 0045 | Ireland: 1800 333 111 | Fax: UK: 0844 801 0046 | Ireland: 1800 333 112 | E-mail: medinfo.uk.ie@celgene.com

For BMS Heritage Medicines: Adverse Event Reporting / MI Enquiries
Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1 800 749 749 (Ireland).
For any medical or product related enquiries relating to a BMS product please contact BMS Medical Information: Telephone: UK: 0800 731 1736 | Ireland: 1 800 749 749 | E-mail: medical.information@bms.com
BMS online Medical Information resource: http://www.globalbmsmedinfo.com

NOUK2000245-01 March 2020